We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00473980
First Posted: May 16, 2007
Last Update Posted: April 2, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Göteborg University
  Purpose
The study is designed to evaluate effects of NSAIDs on immune activity inside and close to tumor tissue in patients with colorectal cancer.

Condition Intervention Phase
Colorectal Cancer Drug: Indomethacin, celecoxib, esomeprazole Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preoperative Treatment With NSAID in Colorectal Cancer Patients in Relationship to Tumor Host Reactions

Resource links provided by NLM:


Further study details as provided by Göteborg University:

Primary Outcome Measures:
  • Immune reactivity [ Time Frame: Acute evaluations ]

Enrollment: 28
Study Start Date: December 1998
Study Completion Date: May 2007
Arms Assigned Interventions
Experimental: Drug
Treatment with indomethacin or celecoxib
Drug: Indomethacin, celecoxib, esomeprazole
Sham Comparator: SHAM
Sham treatment
Drug: Indomethacin, celecoxib, esomeprazole

Detailed Description:
Study and control patients are randomized to receive preoperative treatment with indomethacin or celecoxib compared to sham treatment.Tumor biopsies are taken at operation and used for analyses of tumor immunity and gene expression.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Colon carcinoma scheduled for curative operation

Exclusion Criteria:

  • Diabetes, steroid medication, liver and kidney impairment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00473980


Locations
Sweden
Department of Surgery
Göteborg, Sweden, SE 41345
Sponsors and Collaborators
Göteborg University
Investigators
Principal Investigator: Kent Lundholm, MD, prof Göteborg University
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00473980     History of Changes
Other Study ID Numbers: kl4501122
First Submitted: May 15, 2007
First Posted: May 16, 2007
Last Update Posted: April 2, 2012
Last Verified: March 2012

Keywords provided by Göteborg University:
MHC
CTLs
Colon carcinoma
NSAID
Survival

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Celecoxib
Indomethacin
Anti-Inflammatory Agents, Non-Steroidal
Esomeprazole
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Gout Suppressants